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Background: Echocardiography can detect calcium deposits in heart valves and aortic root, but the relationship of
echocardiographic heart calciﬁcation such as aortic valve calciﬁcation (AVC), mitral annular calciﬁcation (MAC),
and aortic root calciﬁcation (ARC) with future cardiovascular disease (CVD) mortality and morbidity is not fully
elucidated.
Methods:We analyzed data from 943 patients with suspected coronary heart disease (mean age, 65.7 years; 36%
female). Echocardiographic total heart calciﬁcation (THC) score was determined by summing up the AVC, MAC,
and ARC variables; THC-0 (N = 397), THC-1 (N = 236), THC-2 (N = 224), and THC-3 (N = 86). Subjects were
followed for mean 2.9 years to assess the risk of death from CVD causes. Cardiovascular morbidity was deﬁned
as new episodes of non-fatal myocardial infarction, congestive heart failure, stroke, and surgical treatment of
vascular disease.
Results: There were 43 CVD deaths and a total of 160 CVD events. Kaplan–Meier curves showed a graded CVD
mortality and morbidity across increasing THC score values. With full adjustment, Cox regression hazard ratios
(95% conﬁdence intervals) for CVD mortality and morbidity, using no calciﬁcation as reference, for THC-1,
THC-2, and THC-3 were 2.21 (1.31–3.74), 2.59 (1.53–4.39) and 4.14 (2.30–7.47), respectively. When THC score
was added to models with CVD risk factors, C-statistics were signiﬁcantly larger for CVD mortality (p = 0.048)
and for CVD mortality and morbidity (p = 0.004).
Conclusions: THC score, the sumof the amounts of AVC,MAC, and ARC present as estimated by echocardiography,
has an independent and incremental prognostic value in a high-risk population.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Calcium deposits in heart valves, such as aortic valve calciﬁcation
(AVC) and mitral annular calciﬁcation (MAC), have been considered
incidental echocardiographic ﬁndings with no clinical signiﬁcance unless
they cause signiﬁcant blood ﬂow obstruction. However, recent data have
shown that both AVC and MAC are active and highly regulated processes
with histological similarities to atherosclerosis [1]. Several community-
based cohort studies have suggested a strong association of AVC and
MAC with traditional cardiovascular disease (CVD) risk factors [2,3], and
these valvular calciﬁcations are strongly associated with an increased
risk of CVD events and death in the general population [4–6]. Similarly,
as part of thoracic aortic calciﬁcation, the presence of aortic root calciﬁca-
tion (ARC) has been independently associated with an increased risk of
CVD mortality [7]. Coronary artery calcium is a marker of subclinicalascular Medicine, Hiroshima
nces, 1-2-3 Kasumi, Minami-ku,
81 82 257 1569.
mamoto).
. Open access under CC BY-NC-ND licecoronary atherosclerosis and is an established predictor of future coronary
heart disease (CHD) events independent of traditional CVD risk factors [8].
However, information on an association between calciﬁed atherosclerosis
in the coronary artery, heart valves, and aortic root is currently limited
[9,10], and no large observational studies have examined the relationship
of echocardiographic AVC, MAC and ARC with future CVD mortality and
morbidity. The aims of this study were to evaluate the associations of
AVC, MAC, and ARC with calciﬁed coronary atherosclerosis, and to test
the ability of total heart calciﬁcation (THC) score determined by echocar-
diography for the prediction of future CVD mortality and morbidity in a
sample of individuals with suspected CHD referred for clinically indicated
echocardiography and computed tomography (CT).
2. Methods
2.1. Study population
The studywas performed as an observational longitudinal study of chronic complica-
tion in patients with suspected CHD attending the cardiovascular outpatient clinic at
Hiroshima University Hospital. We analyzed the data from outpatients suspected to
have CHD who attended our clinic and underwent coronary CT angiography duringnse.
16 H. Utsunomiya et al. / IJC Heart & Vessels 2 (2014) 15–20the years 2005–2011. Of these, we selected all patients with suspected CHD who had un-
dergone a ﬁrst echocardiography and CT examination no more than 1 month apart for
clinical reasons (chest symptoms, N = 343; asymptomatic with ischemic ﬁndings,
N = 129; and asymptomatic with multiple CVD risk factors, N = 471) at our institution.
Patients with known CHD by previous invasive coronary angiography, prior coronary
stenting and/or bypass surgery, advanced malignancies, and with follow-up periods
shorter than 1 year were excluded. On the basis of these criteria, 943 patients (603 men
and 340 women; mean age, 65.7 ± 11.2 years) suspected to have CHD were identiﬁed
and included in theﬁnal analysis. The studywas approved by thehospital's ethics commit-
tee, and written informed consent was obtained from all patients.
2.2. Risk factor assessment
Overnight fasting blood samples were collected and serum levels of total cholesterol,
low-density cholesterol, high-density cholesterol, and triglyceride and hemoglobin A1C
level were measured. Hypertension was deﬁned as blood pressure greater than 140/
90 mm Hg or current use of hypertensive medication for this condition. Diabetesmellitus
was deﬁned as having a fasting plasma glucose level greater than 126 mg/dL or current
use of hypoglycemic medication. Dyslipidemia was deﬁned as having a fasting serum
total cholesterol level greater than 200 mg/dL or current use of a lipid-lowering medica-
tion. Cigarette smoking was considered present if a subject had smoked at least one
cigarette per day in the last year. A family history of early CHD was considered present if
a patient's immediate family had had non-fatal myocardial infarction, coronary revascu-
larization, or a fatal cardiovascular event before the age of 55. Glomerular ﬁltration rate
(eGFR) was estimated from the four-variable Modiﬁcation of Diet in Renal Disease study
equation.
2.3. Echocardiography and CT imaging
Complete echocardiographic studies of all patients were performed at our institution
with a commercially available system (Vivid 7, GE Healthcare, Milwaukee, WI; or iE33,
Philips Medical Systems, Andover, MA) by four experienced sonographers who were
blinded to the clinical and CT information. Apical 4- and 2-chamber views were acquired
for calculation of left ventricular ejection fraction and left atrial volume using themodiﬁed
Simpson's formula [11]. Left ventricular mass was calculated using the area–length
method and indexed to body surface area. AVC was deﬁned as focal or diffused calciﬁca-
tion and thickening of the aortic leaﬂets/annulus with or without restriction of leaﬂet
motion using the criteria of Otto et al. [6] (Fig. 1A). MAC was deﬁned by increased
echogenicity located at the junction of the atrioventricular groove and posterior mitral
leaﬂet on the parasternal long-axis, short-axis, or apical 4-chamber view [12] (Fig. 1B).
ARC was deﬁned as a focal area of increased echogenicity and thickening in the aortic
root on the parasternal long-axis view [13] (Fig. 1C). In accord with a previous study, we
calculated a THC score thatwas graded from0 to amaximumof 3 according to thenumber
of anatomic sites involved; namely, at the aortic valve, the mitral annulus, and/or the
aortic root [13].
CT examinations were performed using a 64-multidetector CT scanner (LightSpeed
VCT, GE Healthcare). Prospective electrocardiogram-triggered scans were performed
from the root of aorta to the apex of the heart with the following parameters: axial
scan; gantry rotation times, 350 ms; X-ray exposure times, 233 ms; tube voltage,
120 kV; tube currents, 140 mA; center of imaging window, 75% of R-R. Thirty-ﬁve to 40
contiguous images of 2.5-mm thickness were obtained. Coronary artery calcium score
was calculated based on the Agatstonmethod with dedicated software (Smartscore, version
3.5, GE Healthcare) [14]. In addition, we used non-contrast CT datasets to score AVC, MAC,
and ARC with the same software.
2.4. Study outcomes
Subjectswere followed for amean duration of 2.9 years (range 1.0–7.4 years). Patient
information was obtained from medical records or telephone interviews with patients or
their families. Ascertainment of CVD eventswas conducted bypersonswhowere unawareA B
Fig. 1. Examples of determining the THC score. Two-dimensional echocardiographic images sho
aortic root calciﬁcation (C, broken arrow). THC score was determined by summing these extraof the baseline data and echocardiographic results. The primary outcome for the present
study was the occurrence of incident CVD events [6], including death from CVD causes
and CVD morbidity deﬁned as new episodes of non-fatal myocardial infarction, unstable
angina pectoris, congestive heart failure, stroke, and surgical treatment of vascular or
valvular disease. Coronary revascularization was not included in CVD events.
2.5. Statistical analysis
Continuous variables are presented as mean ± SD or median (interquartile range).
Group comparisons of continuous variableswere performed by 1-way analysis of variance
with post-hoc analysis using the Tukey's method. Multivariate logistic analyses included
valvular and aortic root calciﬁcation and were adjusted for age, gender, eGFR, body mass
index, and the traditional CVD risk factors. Event rates were estimated by Kaplan–Meier
curves and compared by log-rank tests stratiﬁed by the presence of AVC, MAC, and ARC
or THC scores. The Cox proportional hazard model was used to calculate univariate and
multivariate hazard ratios (HRs) for the occurrence of incident CVDmortality andmorbid-
ity. The independent predictive values of the presence of AVC, MAC, and ARC or THC score
were assessed in the following hierarchical models: model 1, unadjusted; model 2, adjusted
for age and gender; model 3, model 2 plus eGFR and the traditional CVD risk factors; and
model 4, model 2 plus left ventricular ejection fraction b 50%, left atrial volume, and left
ventricular mass index determined by echocardiography. In addition, we used natural log-
transformed AVC, MAC, ARC, and coronary artery calcium scores for the analyses in which
the quantity of calcium was used. Receiver operating characteristic analyses were
conducted from logistic regression models and the probability values were compared
between different models using the method described by DeLong et al. [15]. All statistical
analyses were performed using SPSS software (version 16.0: SPSS Inc., Chicago, IL). A
probability value of b0.05 was considered signiﬁcant.
3. Results
3.1. Baseline characteristics
There were 441 subjects (46.8%) with AVC, 145 (15.4%) with
MAC, and 344 (36.5%) with ARC. Overall, 397 patients (42.1%) were
free of any calciﬁcation at the valve and aortic root levels (i.e., THC-0),
236 patients (25.0%) had isolated AVC, isolated MAC, or isolated ARC
(i.e., THC-1), and 224 patients (23.8%) had the combined presence of
calcium deposits in any two areas (i.e., THC-2). The remaining 86
patients (9.1%) had the combined presence of calcium deposits in
all three areas (i.e., THC-3). Table 1 summarizes baseline clinical charac-
teristics, echocardiographic measurements, and CT ﬁndings stratiﬁed
by THC scores. Left ventricular ejection fraction was preserved in all
groups, but the THC-3 group had larger left atrial volume and higher
left ventricular mass, indicating impairment of diastolic function.
3.2. Relationship between coronary artery calcium and AVC, MAC, and ARC
As shown in Table 1, coronary artery calcium score escalated in
proportion with THC scores (all p b 0.001 by ANOVA). Overall, the age-
and gender-adjusted Pearson's correlation coefﬁcient between AVC
and coronary artery calcium score was 0.33 (p b 0.001). Similarly, the
amount of MAC and ARCwas fairly correlated with coronary artery calci-
um score (r = 0.18, p b 0.001; r = 0.42, p b 0.001, respectively). With
adjustment for age, gender, CVD risk factors, and the presence of calciumC
waortic valve calciﬁcation (A, solid arrow),mitral annular calciﬁcation (B, arrowhead), and
coronary calciﬁcations. It was calculated to be 3.
Table 1
Baseline characteristics stratiﬁed by total heart calciﬁcation (THC) score.
THC score
THC-0 THC-1 THC-2 THC-3
(N = 397) (N = 236) (N = 224) (N = 86)
Age (yrs) 59 ± 11 68 ± 8⁎ 71 ± 8⁎,† 76 ± 7⁎,†,‡
Male, N (%) 269 (68) 150 (64) 146 (65) 38 (44)⁎,†,‡
Body mass index (kg/m2) 24 ± 5 24 ± 3 24 ± 3 24 ± 4
eGFR (mL/min/1.73 m2) 73 ± 16 70 ± 16 67 ± 17⁎ 62 ± 16⁎,†
Hypertension, N (%) 206 (52) 177 (75)⁎ 178 (80)⁎ 74 (86)⁎,†
Diabetes mellitus, N (%) 97 (24) 77 (33)⁎ 95 (42)⁎,† 41 (48)⁎,†
Dyslipidemia, N (%) 173 (44) 133 (56)⁎ 140 (63)⁎ 50 (58)⁎
Cigarette smoker, N (%) 106 (27) 73 (31) 84 (38)⁎ 18 (21)‡
Family history of early coronary heart disease, N (%) 39 (10) 34 (14) 24 (11) 12 (14)
Total cholesterol (mg/dL) 199 ± 38 195 ± 37 195 ± 32 193 ± 37
Triglycerides (mg/dL) 118 (87–170) 114 (87–171) 127 (91–181) 114 (82–171)
HDL cholesterol (mg/dL) 62 ± 17 58 ± 16⁎ 60 ± 16 63 ± 22
LDL cholesterol (mg/dL) 117 ± 32 117 ± 32 114 ± 28 111 ± 30
HbA1C (%) 5.5 (5.2–6.0) 5.7 (5.3–6.3)⁎ 5.8 (5.4–6.5)⁎,† 5.7 (5.2–6.8)⁎
Left ventricular ejection fraction (%) 64 ± 9 65 ± 10 67 ± 9⁎ 69 ± 11⁎,†
Left atrial volume index (mL/m2) 31 ± 9 33 ± 9 33 ± 9 37 ± 12⁎,†,‡
Left ventricular mass index (g/m2) 84 ± 24 89 ± 25 90 ± 22⁎ 103 ± 36⁎,†,‡
Coronary artery calcium score 2 (0–48) 66 (3–243)⁎ 272 (87–625)⁎,† 344 (128–958)⁎,†
⁎ p b 0.05 vs THC-0.
† p b 0.05 vs THC-1.
‡ p b 0.05 vs THC-2.
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all independently correlated with coronary artery calcium score (β [95%
CI] 0.17 [0.25–0.52], p b 0.001; 0.20 [0.02–0.37], p = 0.026; 0.66
[0.53–0.80], p b 0.001, respectively).3.3. Survival analysis
The average time from initial echocardiography and CT examination
to censoring due to either CVD events or end of study was 2.9 years. As
of May 31, 2013, there were 43 (4.6%) deaths from CVD causes. Incident
CVD events occurred in 160 (17.0%) patients. The breakdown of CVD
events was as follows: CVD death in 43 patients (26.9%), non-fatalmyo-
cardial infarction in 8 (5.0%), unstable angina in 13 (8.1%), congestive
heart failure in 23 (14.4%), stroke in 47 (29.4%), and surgical treatment
of vascular and valvular disease in 26 (16.3%).No
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Fig. 2. (A)Kaplan–Meier survival analysis for CVDmortality stratiﬁed by thepresence of calcium
AVC. (B) Kaplan–Meier survival analysis for CVDmortality andmorbidity stratiﬁed by the prese
vs ARC, MAC vs AVC.Fig. 2 shows Kaplan–Meier survival curves for incident CVD mortal-
ity and CVD mortality and morbidity as functions of valvular and aortic
root calciﬁcation, respectively. For all sites of calciumdeposits and com-
paredwith the absence of calcium at any site, the presence of calcium in
any valve or the aortic root was associated with a signiﬁcantly lower
survival (p b 0.001 for all). For CVD mortality, those with MAC had
the lowest probability of survival, whereas those without AVC had the
highest probability. The survival curves showed the largest separation
for the presence/absence of MAC. When calcium was present, the
curve for MAC was signiﬁcantly different from the curves for AVC and
ARC (p b 0.05 for both). When calcium was absent, there were no
signiﬁcant differences in the survival curves among the different sites
of calcium deposits. Similar results were found for CVD mortality and
morbidity.
Fig. 3 shows Kaplan–Meier survival curves for incident CVD mortal-
ity and CVDmortality and morbidity as functions of the THC score. THCEv
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Fig. 3. (A) Kaplan–Meier survival analysis for CVD mortality stratiﬁed by THC score. (B) Kaplan–Meier survival analysis for CVD mortality and morbidity stratiﬁed by THC score.
18 H. Utsunomiya et al. / IJC Heart & Vessels 2 (2014) 15–20score was strongly associated with an increased risk of CVD death and
events. The differences among these curves were statistically signiﬁcant
for CVDmortality (p b 0.0001 by the log-rank test). Similar results were
found for CVD mortality and morbidity.
3.4. Association of the presence of AVC, MAC, and ARC with CVD mortality
and morbidity
Table 2 lists the univariate and multivariate HRs for CVD mortality
and for CVD mortality and morbidity in the presence of valvular and
aortic root calciﬁcation. In Cox univariate analyses, the presence of cal-
cium in any of the sites was associated with a signiﬁcantly increased
HR for CVD mortality (model 1). Using THC-0 as reference, the univari-
ate HRs were 2.75 (0.90–8.40), 5.83 (2.16–15.7) and 9.87 (3.47–28.0)
for CVDmortality for THC-1, THC-2, and THC-3, respectively. Additional
adjustment for eGFR and the traditional CVD risk factors attenuated the
magnitudes of the associations such that only the presence of MAC or
THC-3 remained statistically signiﬁcantly associated with incident CVD
mortality, with the largest magnitude of associations being for THC-3
(models 2 and 3). Themagnitudes of the associations with CVDmortal-
ity and morbidity were stronger than those with CVD mortality. THCTable 2
Univariate and multivariate-adjusted hazard ratios (HRs) for cardiovascular disease (CVD) mo
Cox regression analyses using hierarchical models
Model 1 Model 2
HR 95% CI p value HR 95% CI p v
CVD mortality
AVC presence 4.02 1.93–8.39 b0.001 1.98 0.92–4.25 0.0
MAC presence 4.41 2.42–8.06 b0.001 2.58 1.37–4.85 0.0
ARC presence 2.65 1.44–4.88 0.002 1.37 0.72–2.60 0.3
THC-0 1.00 Ref. 1.00 Ref.
THC-1 2.75 0.90–8.40 0.076 1.52 0.49–4.75 0.4
THC-2 5.83 2.16–15.7 b0.001 2.47 0.86–7.09 0.0
THC-3 9.87 3.47–28.0 b0.001 3.62 1.18–11.2 0.0
CVD mortality and morbidity
AVC presence 2.94 2.08–4.15 b0.001 1.98 1.36–2.87 b0
MAC presence 2.97 2.13–4.13 b0.001 2.12 1.48–3.02 b0
ARC presence 2.75 2.00–3.78 b0.001 1.93 1.38–2.71 b0
THC-0 1.00 Ref. 1.00 Ref.
THC-1 3.15 1.91–5.20 b0.001 2.41 1.43–4.05 0.0
THC-2 4.27 2.65–6.87 b0.001 2.93 1.76–4.90 b0
THC-3 7.34 4.36–12.3 b0.001 4.74 2.65–8.48 b0
Model 1: unadjusted; model 2: adjusted for age and gender; model 3: adjusted for age, gende
dyslipidemia, cigarette smoking, and family history of early coronary heart disease; model 4:
and left ventricular mass index as detected by means of echocardiography.score and presence of calcium at any of the sites were associated with
a signiﬁcantly increased HR even after adjustment for CVD risk factors.
The largest HR was found for the THC-3 (HR, 4.14 [2.30–7.47]). The re-
sults remained essentially unchanged after adjustment for age, gender,
and other baseline echocardiographic parameters (model 4).
3.5. Model comparisons using receiver operating characteristic analyses
Comparedwith the areas under the curve when the presence of each
valvular and aortic root calciﬁcation was separately added to the CVD
risk factors, the area under the curve was larger for all comparisons
when THC score was added to the CVD risk factors (area under the
curve, 0.833 for CVD mortality, p = 0.048 vs CVD risk factors; 0.770 for
CVD mortality and morbidity, p = 0.004 vs CVD risk factors) (Table 3).
4. Discussion
In this “real-world” cohort study of individuals with suspected CHD,
valvular and aortic root calciﬁcation detected by echocardiography
were associated with calciﬁed atherosclerosis in the coronary arteries
and higher risk of CVD mortality and morbidity. We demonstrate thatrtality and morbidity.
Model 3 Model 4
alue HR 95% CI p value HR 95% CI p value
82 1.72 0.79–3.73 0.170 1.70 0.78–3.70 0.182
03 2.51 1.31–4.78 0.005 2.45 1.29–4.63 0.006
43 1.17 0.60–2.28 0.655 1.53 0.79–2.95 0.207
1.00 Ref. 1.00 Ref.
73 1.24 0.39–3.91 0.713 1.32 0.42–4.16 0.634
93 2.03 0.70–5.90 0.196 2.71 0.92–7.94 0.069
25 2.95 1.04–9.18 0.045 3.27 1.05–10.2 0.041
.001 1.80 1.24–2.63 0.002 1.74 1.16–2.62 0.007
.001 2.06 1.44–2.94 b0.001 1.95 1.33–2.84 0.001
.001 1.75 1.24–2.48 0.002 1.95 1.36–2.80 b0.001
1.00 Ref. 1.00 Ref.
01 2.21 1.31–3.74 0.003 1.97 1.13–3.44 0.016
.001 2.59 1.53–4.39 b0.001 2.94 1.71–5.05 b0.001
.001 4.14 2.30–7.47 b0.001 3.72 1.96–7.08 b0.001
r, estimated glomerular ﬁltration rate, body mass index, hypertension, diabetes mellitus,
adjusted for age, gender, left ventricular ejection fraction b 50%, left atrial volume index,
Table 3
Areas under the curve from receiver operating characteristic analyses.
CVD mortality CVD mortality and morbidity
Model AUC 95% CI p value AUC 95% CI p value
Traditional risk factors (TRFs)a 0.818 0.755–0.880 Ref. 0.735 0.693–0.778 Ref.
TRFs + AVC presence 0.824 0.761–0.888 0.14 0.754 0.714–0.794 0.02
TRFs + MAC presence 0.824 0.760–0.888 0.15 0.748 0.705–0.791 0.05
TRFs + ARC presence 0.818 0.755–0.880 0.49 0.751 0.709–0.793 0.04
TRFs + THC score 0.833 0.773–0.893 0.048 0.770 0.731–0.810 0.004
a Includes age, gender, hypertension, diabetes mellitus, dyslipidemia, cigarette smoking, and family history of early coronary heart disease.
19H. Utsunomiya et al. / IJC Heart & Vessels 2 (2014) 15–20the prognostic value of echocardiographic THC score is independent of
CVD risk factors, renal function (eGFR), and baseline echocardiographic
variables. C-statistics from receiver operating characteristic analyses
revealed that THC score had an incremental ability to predict CVD
mortality and CVD mortality and morbidity compared to traditional
risk factors.
4.1. Valvular and aortic root calciﬁcation and coronary atherosclerosis
AVC,MAC, and ARC are common abnormal ﬁndings on echocardiog-
raphy in the elderly [3,6,13]. Previous studies have suggested that these
calciﬁcations are not simply a degenerative change but an active and
highly regulated process with several pathogenic features in common
with atherosclerosis, including the process of lipid deposition, macro-
phage and T-cell inﬁltration, and induction of osteoblast-like phenotype
[16]. Until now, several electron-beam CT studies have investigated the
relationship amongAVC,MAC, ARC, and CAC,mainly in the general pop-
ulation [9,10]. In addition, these valvular and aortic root calciﬁcation are
not only related to coronary atherosclerosis, but also to atherosclerosis
in other vascular beds, such as the carotid, abdominal, or iliac arteries
in asymptomatic patients without known CHD [17]. The ﬁndings in
those studies, however, were not sufﬁciently validated in a high-risk
population such as patients with suspected CHD and the prognostic
value of echocardiographic heart calciﬁcation remains to be investigat-
ed. The results of our study provide novel information on AVC, MAC,
and ARC as reliable markers of the severity of systemic atherosclerosis,
including in the coronary arteries. It should also be noted that in our
study, AVC, MAC, and ARC scores were only fairly correlated with coro-
nary artery calcium score. It is also possible to speculate that the twodif-
ferent phases of extracoronary calcium progression: the early phase,
when calcium deposits appear de novowith progressive atherosclerosis,
and the secondary phase, when established calcium deposits progress
independently of CVD risk factors and grow faster with other conditions
such as chronic inﬂammation which may predispose patients to an
active calciﬁcation process.
4.2. Valvular and aortic root calciﬁcation as an indicator of future CVD
events
Until now, there is limited information on echocardiographic heart
calciﬁcation and future CVD events in the literature. The Cardiovascular
Health Study showed that the presence of AVC is associated with an
approximately 50% increase in the risk of CVD mortality and morbidity
in adults age N 65 years [6]. Echocardiographic presence and severity
of MAC have been directly related to increased risk of CVD events,
including acute myocardial infarction, stroke, and vascular diseases
[5,12]. In contrast, several studies have shown that ARC is closely asso-
ciated with CVD events but that the prognostic value of ARC generally
diminishes with adjustment for age, CVD risk factors, and CAC [7,18].
Also in the present study, the predictive value of ARC for CVDmortality
altered nonsigniﬁcantly after full adjustment. Meanwhile, AVC, MAC,
and ARC are strongly associated with CVD mortality and morbidity
independent of CVD risk factors, renal function, and other echocardio-
graphic variables.4.3. Clinical implication
Our study also provides an interesting ﬁnding that THC score — the
sumof the amount of AVC,MAC, and ARC present as estimated by echo-
cardiography — has an independent prognostic value associated with
CVD mortality and morbidity. Importantly, based on the receiver oper-
ating characteristic analyses, this study indicates that THC score can
provide additional information for discriminating CVD events beyond
that provided by traditional CVD risk factors. Recent studies demon-
strated that the combination of AVC and MAC is indicative of more
extensive coronary atherosclerotic plaques [19] and improves the pre-
dictive power with respect to all-cause mortality and CVD mortality
[20,21]. Furthermore, echocardiographic THC score is correlated with
the presence of obstructive CHD and the presence of inappropriate
high left ventricular mass index [22]. The result of our study suggests
that the combined presence of AVC, MAC, and ARC (i.e. THC-3) is indic-
ative of more critical disease states, such as extensive systemic athero-
sclerosis, concomitant diastolic dysfunction due to high left ventricular
mass, and valve insufﬁciency, andmay therefore be signiﬁcantly associ-
ated with incident CVD mortality and morbidity.
Thus far, great attention has been paid to the prognostic value of cor-
onary artery calcium score as measured by CT for both all-cause and
CVD mortality [7,8,18]. However, the evaluation of coronary artery cal-
cium has several disadvantages, such as radiation exposure and high
cost. Echocardiographic THC score overcomes these limitations and re-
quires no special equipment, extra imaging time, or considerable effort
to analyze, so this index is easy to implement for routine applications.
Therefore, from a clinical perspective, heart calciﬁcation on routine
echocardiography should not be overlooked and can be used for risk
stratiﬁcation. It can help identify patients appropriate for intensive
medical treatment to inhibit an active atherosclerotic process.
4.4. Study limitations
First, all patientswere suspected to have CHD and had clinical reasons
for coronary CT assessment; thus, they had relatively high pretest proba-
bility. Thus, our results do not apply to patients with a lower probability
of CHD.However, patients such as those fromour study are themost like-
ly to need detailed risk stratiﬁcation in daily clinical practice. The second
limitation of this study is its retrospective and longitudinal design, which
does not allow us to draw any conclusions about causality. Therefore, the
results should be interpreted with extreme caution. Larger prospective
follow-up studies are necessary to conﬁrm our ﬁndings and to determine
whether therapeutic intervention in the progression of calciﬁc aortic and
valvular disease can decrease risk of developing CVD death and cardiac
events in a high-risk population. Third, in this study, detailed data regard-
ing medication use and plasma levels of inﬂammatory markers, such as
C-reactive protein and adipokines,were not collected. The potential effect
of this information on the results is not clear.
Finally, the results of this study should not be construed as support
for coronary CT angiography scans for the sole purpose of CVD risk
assessment. Rather, routine echocardiography examinations may be
most relevant as “gatekeepers of the application of coronary CT angiog-
raphy” because the echocardiographic images of heart calciﬁcation
20 H. Utsunomiya et al. / IJC Heart & Vessels 2 (2014) 15–20were found in our study to have strong and signiﬁcant associationswith
extensive coronary atherosclerosis and increased risk of future CVD
events.
5. Conclusions
Our study demonstrates that AVC, MAC, and ARC detected by echo-
cardiography, singly or in combination, are independently and additively
predictive of CVD mortality and morbidity in patients with suspected
CHD.
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